2nd Annual CMOD Canadian Biomarkers and Surrogate Endpoints Meeting

“Biomarkers and Personalized Medicine”
May 17, 2010

Banting Theatre, Health Canada Campus  - Tunney’s Pasture, Ottawa, Ontario


Opening Remarks and Introduction
The Personalized Medicine LandscapeClarissa Desjardins, CEPMED
Rewards and Risks of Using Biomarkers in Drug DevelopmentAgnes Klein, Health Canada
CIHR Initiatives - Advancing Research and Practice - Peter Liu, CIHR/ U Toronto
Streamlining drug development and clinical trials with biomarkersJ-C Tardif, Montreal Heart
GWAS, Sequencing and Integrative BiologyJohn Rioux, Montreal Heart Institute
Pharmacogenomics: A Research ProspectiveMichael Phillips, Montreal Heart Institute
Novel Approaches and Clinical UtilityPeter Libby, Harvard Medical School
Clopidogrel and Genetic VarianceJessica Mega, Brigham and Women’s Hospital
Hepatic SafetyBrian Foster, Health Canada
Providing Personalized Medicine with Molecular ImagingDonald Black, CMOD
Case studies: Pharma / Diagnostic
Science Policy Perspectives from the Health PortfolioNarayanan Iyer, Health Canada
Panel Discussion

Patient Selection Strategies for the Development of MDM2 Inhibitors - Robert Wasserman
Opportunities and Challenges of Rx-Dx Co-Development - Helen Wu, Roche

What is Required to Ensure a Smooth Transition From an R&D Test to a Test Used Within a Clinical Environment? - Patrice Hugo, Clearstone

How can Canada lead in the adoption of personalized medicine strategies?
Conclusion and Adjourn